[Antibacterian activity modifications of serum isoniazid when using it with rifampicin (author's transl)]. 1982

A Nouhouayi, and E Bergogne-Berezin, and C Lafaix

When dosing isoniazid in patients' serum after ingestion, the authors find a difference in the isoniazid levels when isoniazid is used alone, then, when isoniazid is used simultaneously with rifampicin. The level decreases or increases according to the inactivation index. They analyse the therapeutic consequences which can result from it. They infer, from the practical point of view, the necessity of : dosing isoniazid after having ingested it simultaneously with rifampicin and not alone when the efficient therapeutic dose is to be determined ; testing serum levels during antituberculous therapy for an eventual readjustment.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D009161 Mycobacterium A genus of gram-positive, aerobic bacteria. Most species are free-living in soil and water, but the major habitat for some is the diseased tissue of warm-blooded hosts. Mycobacteria
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses

Related Publications

A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
May 1974, Deutsche medizinische Wochenschrift (1946),
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
April 1978, La Nouvelle presse medicale,
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
December 1977, Deutsche medizinische Wochenschrift (1946),
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
May 1980, Kekkaku : [Tuberculosis],
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
June 1977, Revista medica de Chile,
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
December 1981, Anales espanoles de pediatria,
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
September 1979, Deutsche medizinische Wochenschrift (1946),
A Nouhouayi, and E Bergogne-Berezin, and C Lafaix
April 1978, Kekkaku : [Tuberculosis],
Copied contents to your clipboard!